Evidence-Based Recommendations · ACOG · SMFM · NICE
ACOG Practice Bulletin · SMFM Consult Series · NICE NG3
Glycemic targets met with nutrition alone
Requires insulin or oral hypoglycemic agents
Persistent hyperglycemia despite therapy
ACOG Practice Bulletin No. 190
Antepartum fetal testing indicated.
No benefit to delivery before 39 weeks.
ACOG PB No. 190 [1]
Induction at 38–39 wks reduces LGA rates without increasing cesarean delivery
Shoulder dystocia: 1.4% with induction at 38–39 wks vs. 10% with expectant management beyond 40 wks
ACOG PB No. 190 [1]
Balance prematurity risk against stillbirth risk.
No clear glycemic threshold defined by ACOG for "poorly controlled."
ACOG PB No. 190 [1]
Failure of in-hospital attempts to improve glycemic control
Abnormal antepartum fetal surveillance
Reserve for refractory cases only.
Late preterm delivery carries significant neonatal morbidity risk.
ACOG PB No. 190 [1]
Individualized; no universal gestational age threshold
Risk is higher at any fetal weight in diabetic vs. non-diabetic pregnancies
Discuss risks/benefits of scheduled cesarean delivery
Third-trimester ultrasound or clinical exam is reasonable to identify macrosomia.
ACOG PB No. 190 [1] · ACOG PB No. 227 [2]
Induction <39 weeks in well-controlled GDM is associated with increased neonatal morbidity
Reserve early-term delivery for poor glycemic control or concerning fetal status.
ACOG PB No. 190 [1] · Supported by RCT data [5]
Tiered approach by glycemic control class (A1 vs. A2 vs. poor control). Delivery window: 39–406/7 weeks for well-controlled GDM.
Delivery no later than 40+6 weeks for all women with GDM. Earlier elective birth if maternal or fetal complications arise.
Both guidelines converge on avoiding delivery before 39 weeks in uncomplicated, well-controlled GDM.
NICE NG3 [4] · ACOG PB No. 190 [1]
| Clinical Scenario | Recommended Delivery | Key Consideration |
|---|---|---|
|
A1GDM Diet-controlled, well-controlled, normal fetus |
390/7 – 406/7 wks | Expectant management with antepartum testing; no benefit to delivery <39 wks |
|
A2GDM Medication-managed, well-controlled, normal fetus |
390/7 – 396/7 wks | Induction at 38–39 wks may reduce LGA; shoulder dystocia 1.4% vs. 10% |
|
POOR CONTROL Diet or medication, suboptimal glycemia |
370/7 – 386/7 wks | Balance prematurity vs. stillbirth risk; no clear glycemic threshold defined |
|
REFRACTORY Failing inpatient management or abnormal testing |
340/7 – 366/7 wks | Reserve for refractory cases only; significant neonatal morbidity risk |
|
MACROSOMIA EFW ≥ 4,500 g |
Individualized | Counsel re: cesarean delivery; shoulder dystocia risk elevated at any weight |
ACOG PB No. 190 [1] · ACOG PB No. 227 [2] · NICE NG3 [4]